Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Divestments (2018)

Historic Divestments for Lineage Cell Therapeutics (LCTX) over the last 1 years, with Q1 2018 value amounting to $3.2 million.

  • Lineage Cell Therapeutics' Divestments changed N/A to $3.2 million in Q1 2018 from the same period last year, while for Dec 2018 it was $3.2 million, marking a year-over-year change of. This contributed to the annual value of $3.2 million for FY2018, which is N/A changed from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Divestments stood at $3.2 million for Q1 2018.
  • Lineage Cell Therapeutics' Divestments' 5-year high stood at $3.2 million during Q1 2018, with a 5-year trough of $3.2 million in Q1 2018.